Abstract：
OBJECTIVE: Recovery from a COVID-19 infection can lead to post-COVID-19 condition (PCC), which causes a multitude of debilitating symptoms that negatively affect an individual\'s health-related quality of life, including depressive and anxiety symptoms. We aim to examine the mediatory effects of anxiety on depressive symptoms in persons with PCC receiving vortioxetine.
METHODS: We performed a post-hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial investigating vortioxetine treatment on cognitive functioning in persons with PCC. Anxiety and depressive symptoms were measured by the 7-Item Generalized Anxiety Disorder (GAD-7) Scale and the 16-Item Quick Inventory of Depressive Symptomatology (QIDS-SR-16), respectively.
RESULTS: Based on data of 147 participants, GAD-7 scores were significantly positively associated with QIDS-SR-16 scores (β=0.038, 95 % CI [0.029,0.047], p < 0.001). After adjusting for covariates, a significant group (χ2=176.786, p < 0.001), time (χ2=8.914, p = 0.003), and treatment x time x GAD-7 score interaction (χ2=236.483, p < 0.001) effect was observed. Vortioxetine-treated participants had a significant difference in overall change in depressive symptoms (mean difference=-3.15, SEM=0.642, 95 % CI [-4.40,-1.89], p < 0.001).
CONCLUSIONS: Anxiety symptoms were significantly associated with depressive symptoms in persons with PCC. Antidepressant efficacy on ameliorating depressive symptoms is dependent on improving anxiety symptoms, underscoring significant implications in improving treatment efficacy and patient quality of life.
METHODS: We performed a post-hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial investigating vortioxetine treatment on cognitive functioning in persons with PCC. Anxiety and depressive symptoms were measured by the 7-Item Generalized Anxiety Disorder (GAD-7) Scale and the 16-Item Quick Inventory of Depressive Symptomatology (QIDS-SR-16), respectively.
RESULTS: Based on data of 147 participants, GAD-7 scores were significantly positively associated with QIDS-SR-16 scores (β=0.038, 95 % CI [0.029,0.047], p < 0.001). After adjusting for covariates, a significant group (χ2=176.786, p < 0.001), time (χ2=8.914, p = 0.003), and treatment x time x GAD-7 score interaction (χ2=236.483, p < 0.001) effect was observed. Vortioxetine-treated participants had a significant difference in overall change in depressive symptoms (mean difference=-3.15, SEM=0.642, 95 % CI [-4.40,-1.89], p < 0.001).
CONCLUSIONS: Anxiety symptoms were significantly associated with depressive symptoms in persons with PCC. Antidepressant efficacy on ameliorating depressive symptoms is dependent on improving anxiety symptoms, underscoring significant implications in improving treatment efficacy and patient quality of life.
摘要：
目的：从COVID-19感染中恢复可导致COVID-19后病情（PCC），这会导致大量的衰弱症状，对个体的健康相关生活质量产生负面影响，包括抑郁和焦虑症状.我们旨在研究接受沃替西汀的PCC患者焦虑对抑郁症状的中介作用。
方法：我们对随机，双盲,安慰剂对照临床试验研究伏替西汀治疗对PCC患者认知功能的影响.通过7项广泛性焦虑症（GAD-7）量表和16项抑郁症状快速量表（QIDS-SR-16）测量焦虑和抑郁症状，分别。
结果：根据147名参与者的数据，GAD-7评分与QIDS-SR-16评分呈显著正相关(β=0.038,95%CI[0.029,0.047],p<0.001)。在调整协变量后，显著组(χ2=176.786，p<0.001)，时间（χ2=8.914，p=0.003），与治疗时间xGAD-7评分交互作用(χ2=236.483,p<0.001)观察疗效。沃替西汀治疗的参与者在抑郁症状的总体变化方面存在显着差异（平均差异=-3.15，SEM=0.642，95％CI[-4.40，-1.89]，p<0.001)。
结论：PCC患者的焦虑症状与抑郁症状显著相关。抗抑郁药对改善抑郁症状的疗效取决于改善焦虑症状，强调在提高治疗疗效和患者生活质量方面的重要意义。
方法：我们对随机，双盲,安慰剂对照临床试验研究伏替西汀治疗对PCC患者认知功能的影响.通过7项广泛性焦虑症（GAD-7）量表和16项抑郁症状快速量表（QIDS-SR-16）测量焦虑和抑郁症状，分别。
结果：根据147名参与者的数据，GAD-7评分与QIDS-SR-16评分呈显著正相关(β=0.038,95%CI[0.029,0.047],p<0.001)。在调整协变量后，显著组(χ2=176.786，p<0.001)，时间（χ2=8.914，p=0.003），与治疗时间xGAD-7评分交互作用(χ2=236.483,p<0.001)观察疗效。沃替西汀治疗的参与者在抑郁症状的总体变化方面存在显着差异（平均差异=-3.15，SEM=0.642，95％CI[-4.40，-1.89]，p<0.001)。
结论：PCC患者的焦虑症状与抑郁症状显著相关。抗抑郁药对改善抑郁症状的疗效取决于改善焦虑症状，强调在提高治疗疗效和患者生活质量方面的重要意义。
